Selected research
Industry Research
ADCC Enhanced Antibody Industry Research Report 2026
Market perspective
The global ADCC Enhanced Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for ADCC Enhanced Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for ADCC Enhanced Antibody is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for ADCC Enhanced Antibody is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of ADCC Enhanced Antibody include C.H. Boehringer Sohn, Daiichi Sankyo, Jazz Pharmaceuticals, MacroGenics, Merus NV, Novartis AG, Puma Biotechnology, Roche Holding AG and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global ADCC Enhanced Antibody market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
ADCC Enhanced Antibody Market by Company
C.H. Boehringer Sohn
Daiichi Sankyo
Jazz Pharmaceuticals
MacroGenics
Merus NV
Novartis AG
Puma Biotechnology
Roche Holding AG
Takeda Pharmaceutical
Dizal (Jiangsu) Pharmaceutical
Hengrui Medicine
Pfizer
RemeGen Biopharma
Sansheng Guojian
ADCC Enhanced Antibody Segment by Type
Fc Fusion Protein
Monospecific Antibody
Polyspecific Antibody
Antibody Fusion Protein
ADCC Enhanced Antibody Segment by Application
Hospital
Clinic
Others
ADCC Enhanced Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADCC Enhanced Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ADCC Enhanced Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADCC Enhanced Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of ADCC Enhanced Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of ADCC Enhanced Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of ADCC Enhanced Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fc Fusion Protein
- Monospecific Antibody
- Polyspecific Antibody
- Antibody Fusion Protein
Applications
- Hospital
- Clinic
- Others
Companies covered
- C.H. Boehringer Sohn
- Daiichi Sankyo
- Jazz Pharmaceuticals
- MacroGenics
- Merus NV
- Novartis AG
- Puma Biotechnology
- Roche Holding AG
- Takeda Pharmaceutical
- Dizal (Jiangsu) Pharmaceutical
- Hengrui Medicine
- Pfizer
- RemeGen Biopharma
- Sansheng Guojian
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global ADCC Enhanced Antibody Market Size (2021-2032)
- 2.2.2 Global ADCC Enhanced Antibody Sales (2021-2032)
- 2.2.3 Global ADCC Enhanced Antibody Market Average Price (2021-2032)
- 2.3 ADCC Enhanced Antibody by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Fc Fusion Protein
- 2.3.3 Monospecific Antibody
- 2.3.4 Polyspecific Antibody
- 2.3.5 Antibody Fusion Protein
- 2.4 ADCC Enhanced Antibody by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global ADCC Enhanced Antibody Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global ADCC Enhanced Antibody Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global ADCC Enhanced Antibody Revenue of Manufacturers (2021-2026)
- 3.4 Global ADCC Enhanced Antibody Average Price by Manufacturers (2021-2026)
- 3.5 Global ADCC Enhanced Antibody Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of ADCC Enhanced Antibody, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of ADCC Enhanced Antibody, Product Type & Application
- 3.8 Global Manufacturers of ADCC Enhanced Antibody, Established Date
- 3.9 Global ADCC Enhanced Antibody Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 C.H. Boehringer Sohn
- 4.1.1 C.H. Boehringer Sohn Company Information
- 4.1.2 C.H. Boehringer Sohn Business Overview
- 4.1.3 C.H. Boehringer Sohn ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 C.H. Boehringer Sohn ADCC Enhanced Antibody Product Portfolio
- 4.1.5 C.H. Boehringer Sohn Recent Developments
- 4.2 Daiichi Sankyo
- 4.2.1 Daiichi Sankyo Company Information
- 4.2.2 Daiichi Sankyo Business Overview
- 4.2.3 Daiichi Sankyo ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Daiichi Sankyo ADCC Enhanced Antibody Product Portfolio
- 4.2.5 Daiichi Sankyo Recent Developments
- 4.3 Jazz Pharmaceuticals
- 4.3.1 Jazz Pharmaceuticals Company Information
- 4.3.2 Jazz Pharmaceuticals Business Overview
- 4.3.3 Jazz Pharmaceuticals ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jazz Pharmaceuticals ADCC Enhanced Antibody Product Portfolio
- 4.3.5 Jazz Pharmaceuticals Recent Developments
- 4.4 MacroGenics
- 4.4.1 MacroGenics Company Information
- 4.4.2 MacroGenics Business Overview
- 4.4.3 MacroGenics ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MacroGenics ADCC Enhanced Antibody Product Portfolio
- 4.4.5 MacroGenics Recent Developments
- 4.5 Merus NV
- 4.5.1 Merus NV Company Information
- 4.5.2 Merus NV Business Overview
- 4.5.3 Merus NV ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merus NV ADCC Enhanced Antibody Product Portfolio
- 4.5.5 Merus NV Recent Developments
- 4.6 Novartis AG
- 4.6.1 Novartis AG Company Information
- 4.6.2 Novartis AG Business Overview
- 4.6.3 Novartis AG ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis AG ADCC Enhanced Antibody Product Portfolio
- 4.6.5 Novartis AG Recent Developments
- 4.7 Puma Biotechnology
- 4.7.1 Puma Biotechnology Company Information
- 4.7.2 Puma Biotechnology Business Overview
- 4.7.3 Puma Biotechnology ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Puma Biotechnology ADCC Enhanced Antibody Product Portfolio
- 4.7.5 Puma Biotechnology Recent Developments
- 4.8 Roche Holding AG
- 4.8.1 Roche Holding AG Company Information
- 4.8.2 Roche Holding AG Business Overview
- 4.8.3 Roche Holding AG ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Holding AG ADCC Enhanced Antibody Product Portfolio
- 4.8.5 Roche Holding AG Recent Developments
- 4.9 Takeda Pharmaceutical
- 4.9.1 Takeda Pharmaceutical Company Information
- 4.9.2 Takeda Pharmaceutical Business Overview
- 4.9.3 Takeda Pharmaceutical ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Takeda Pharmaceutical ADCC Enhanced Antibody Product Portfolio
- 4.9.5 Takeda Pharmaceutical Recent Developments
- 4.10 Dizal (Jiangsu) Pharmaceutical
- 4.10.1 Dizal (Jiangsu) Pharmaceutical Company Information
- 4.10.2 Dizal (Jiangsu) Pharmaceutical Business Overview
- 4.10.3 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Portfolio
- 4.10.5 Dizal (Jiangsu) Pharmaceutical Recent Developments
- 4.11 Hengrui Medicine
- 4.11.1 Hengrui Medicine Company Information
- 4.11.2 Hengrui Medicine Business Overview
- 4.11.3 Hengrui Medicine ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hengrui Medicine ADCC Enhanced Antibody Product Portfolio
- 4.11.5 Hengrui Medicine Recent Developments
- 4.12 Pfizer
- 4.12.1 Pfizer Company Information
- 4.12.2 Pfizer Business Overview
- 4.12.3 Pfizer ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Pfizer ADCC Enhanced Antibody Product Portfolio
- 4.12.5 Pfizer Recent Developments
- 4.13 RemeGen Biopharma
- 4.13.1 RemeGen Biopharma Company Information
- 4.13.2 RemeGen Biopharma Business Overview
- 4.13.3 RemeGen Biopharma ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 RemeGen Biopharma ADCC Enhanced Antibody Product Portfolio
- 4.13.5 RemeGen Biopharma Recent Developments
- 4.14 Sansheng Guojian
- 4.14.1 Sansheng Guojian Company Information
- 4.14.2 Sansheng Guojian Business Overview
- 4.14.3 Sansheng Guojian ADCC Enhanced Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Sansheng Guojian ADCC Enhanced Antibody Product Portfolio
- 4.14.5 Sansheng Guojian Recent Developments
5 Global ADCC Enhanced Antibody Market Scenario by Region
- 5.1 Global ADCC Enhanced Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global ADCC Enhanced Antibody Sales by Region: 2021-2032
- 5.2.1 Global ADCC Enhanced Antibody Sales by Region: 2021-2026
- 5.2.2 Global ADCC Enhanced Antibody Sales by Region: 2027-2032
- 5.3 Global ADCC Enhanced Antibody Revenue by Region: 2021-2032
- 5.3.1 Global ADCC Enhanced Antibody Revenue by Region: 2021-2026
- 5.3.2 Global ADCC Enhanced Antibody Revenue by Region: 2027-2032
- 5.4 North America ADCC Enhanced Antibody Market Facts & Figures by Country
- 5.4.1 North America ADCC Enhanced Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America ADCC Enhanced Antibody Sales by Country (2021-2032)
- 5.4.3 North America ADCC Enhanced Antibody Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe ADCC Enhanced Antibody Market Facts & Figures by Country
- 5.5.1 Europe ADCC Enhanced Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe ADCC Enhanced Antibody Sales by Country (2021-2032)
- 5.5.3 Europe ADCC Enhanced Antibody Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific ADCC Enhanced Antibody Market Facts & Figures by Country
- 5.6.1 Asia Pacific ADCC Enhanced Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific ADCC Enhanced Antibody Sales by Country (2021-2032)
- 5.6.3 Asia Pacific ADCC Enhanced Antibody Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America ADCC Enhanced Antibody Market Facts & Figures by Country
- 5.7.1 South America ADCC Enhanced Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America ADCC Enhanced Antibody Sales by Country (2021-2032)
- 5.7.3 South America ADCC Enhanced Antibody Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa ADCC Enhanced Antibody Market Facts & Figures by Country
- 5.8.1 Middle East and Africa ADCC Enhanced Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa ADCC Enhanced Antibody Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa ADCC Enhanced Antibody Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global ADCC Enhanced Antibody Sales by Type (2021-2032)
- 6.1.1 Global ADCC Enhanced Antibody Sales by Type (2021-2032) & (Units)
- 6.1.2 Global ADCC Enhanced Antibody Sales Market Share by Type (2021-2032)
- 6.2 Global ADCC Enhanced Antibody Revenue by Type (2021-2032)
- 6.2.1 Global ADCC Enhanced Antibody Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global ADCC Enhanced Antibody Revenue Market Share by Type (2021-2032)
- 6.3 Global ADCC Enhanced Antibody Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global ADCC Enhanced Antibody Sales by Application (2021-2032)
- 7.1.1 Global ADCC Enhanced Antibody Sales by Application (2021-2032) & (Units)
- 7.1.2 Global ADCC Enhanced Antibody Sales Market Share by Application (2021-2032)
- 7.2 Global ADCC Enhanced Antibody Revenue by Application (2021-2032)
- 7.2.1 Global ADCC Enhanced Antibody Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global ADCC Enhanced Antibody Revenue Market Share by Application (2021-2032)
- 7.3 Global ADCC Enhanced Antibody Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 ADCC Enhanced Antibody Value Chain Analysis
- 8.1.1 ADCC Enhanced Antibody Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 ADCC Enhanced Antibody Production Mode & Process
- 8.2 ADCC Enhanced Antibody Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 ADCC Enhanced Antibody Distributors
- 8.2.3 ADCC Enhanced Antibody Customers
9 Global ADCC Enhanced Antibody Analyzing Market Dynamics
- 9.1 ADCC Enhanced Antibody Industry Trends
- 9.2 ADCC Enhanced Antibody Industry Drivers
- 9.3 ADCC Enhanced Antibody Industry Opportunities and Challenges
- 9.4 ADCC Enhanced Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst